<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://peptidebureau.com/fda-glp-1-naion-vision-loss-warning.html</loc>
    <news:news>
      <news:publication><news:name>Peptide Bureau</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-12T16:17:00+00:00</news:publication_date>
      <news:title>FDA Requires a Vision-Loss Warning on All GLP-1 Drugs, From Ozempic and Zepbound to Foundayo</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://peptidebureau.com/hims-hers-peptides-plus-bpc-157-tb-500.html</loc>
    <news:news>
      <news:publication><news:name>Peptide Bureau</news:name><news:language>en</news:language></news:publication>
      <news:publication_date>2026-11-12T16:17:00+00:00</news:publication_date>
      <news:title>Hims &amp; Hers Says Its Peptide Offering Starts This Month, With BPC-157 and TB-500 to Follow &#x27;When the Regulatory Environment Permits&#x27;</news:title>
    </news:news>
  </url>
</urlset>
